Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | FECH | P22830 | 1/20 | 0.42 |
| ▸ | CLK3 | P49761 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122335 | 0.90 | MAOA (0.53) | ALDH1A1LMNACYP1A1CYP1B1CYP1A2 | |
| SCHEMBL1122699 | 0.90 | MAOA (0.53) | ALDH1A1LMNACYP1A1CYP1B1CYP1A2 | |
| SCHEMBL1122313 | 0.90 | ALDH1A1 (0.52) | ALDH1A1LMNACYP1A1CYP1B1CYP1A2 | |
| SCHEMBL1122684 | 0.88 | LMNA (0.54) | ALDH1A1LMNACA1CA2GAA | |
| SCHEMBL1122695 | 0.86 | PTGS2 (0.51) | ALDH1A1LMNACA1CA2PLAU | |
| SCHEMBL1122683 | 0.86 | ALDH1A1 (0.48) | ALDH1A1LMNACYP1A1CYP1B1CYP1A2 | |
| SCHEMBL826254 | 0.85 | ALDH1A1 (0.47) | ALDH1A1LMNACYP1A1CYP1B1CYP1A2 | |
| SCHEMBL826253 | 0.85 | ALDH1A1 (0.47) | ALDH1A1LMNACYP1A1CYP1B1CYP1A2 | |
| SCHEMBL828284 | 0.85 | NQO2 (0.48) | ALDH1A1LMNACYP1A1CYP1B1ABCG2 | |
| SCHEMBL30527938 | 0.85 | ALDH1A1 (0.47) | ALDH1A1LMNACYP1A1CYP1B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379508-B9 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2011-02-09 | — | — | EP | claimed |
| EP-1379508-B1 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2010-09-01 | — | — | EP | claimed |
| EP-1379508-A4 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2005-12-28 | — | — | EP | claimed |
| EP-1379508-A2 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2004-01-14 | — | — | EP | claimed |
| US-6646009-B2 | Use against proliferative disorders including cancer, and as a radioprotective compound for normal cells from ionizing radiation | Temple University — Of Commonwealth System of Higher Education | 2003-11-11 | — | — | US | claimed |
| US-20020165412-A1 | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | ONCONOVA THERAPEUTICS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002067865-A2 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-06 | — | — | WO | claimed |
| EP-1379508-B9 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2011-02-09 | — | — | EP | disclosed |
| EP-1379508-B1 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2010-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165412-A1 | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | HCCS, NAT1, ARSA | ALDH1A1 678/4885LMNA 3112/4885CYP1A1 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.